Continuous Rifampicin Therapy Induced Acute Kidney Injury in a Tuberculous Patient: A Case Report


  • Muqsit Ali Shaukat Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Medicine at Federal Government Polyclinic Hospital, Islamabad Pakistan.
  • Muhammad Fahad Ali Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Surgery at Pakistan Institute of Medical Sciences (PIMS), Islamabad Pakistan.
  • Ahmed Irtaza Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Medicine at Khyber Teaching Hospital, Peshawar.
  • Shehroz Yar Khan Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Medicine at Lady Reading Hospital, Peshawar, Pakistan.
  • Shad Muhammad Khan Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Medicine at Khalifa Gul Nawaz Teaching Hospital, Bannu, Pakistan.
  • Sohail Babar Bachelor of Medicine and Bachelor of Surgery (MBBS). Resident Physician in General Medicine at Mufti Mehmood Memorial Teaching Hospital, Dera Ismail Khan, Pakistan.



Anti-tuberculosis, Rifampicin, Isoniazid, acute kidney injury, Tuberculosis.


Background: Tuberculosis (TB) presents with productive cough, hemoptysis, chest pain, fever, weight loss, and night sweats. Anti-tuberculosis treatment (ATT) can affect various organs, including the liver and kidneys. ATT-induced acute kidney injury (AKI) presents with fever, rash, nausea, vomiting, diarrhea, and abdominal pain. It occurs due to type 2 or 3 hypersensitivity and affects individuals who have previously used rifampicin or are currently using it intermittently.

Case: An 60-year-old lady was diagnosed with TB and started on ATT. After a few days, she complained of reduced food intake and vomiting, yellow discoloration of the skin, abdominal pain and distention, and limb swelling. She was diagnosed as a case of ATT-induced AKI. She didn't have past exposure to rifampicin and was continuously using it this time.

Conclusion: The key learning point from this case is that ATT-induced AKI can develop even when used in a continuous dosing regime and upon first time exposure despite no history of past exposure. This prompts vigilance in monitoring renal function in patients being started on ATT regimen. This is becasuse, ATT-induced AKI poses risk to patient’s life and there is a possibility of developing resistance to anti-tuberculous therapy as a result of discontinuation of treatment. Furthermore, our case suggests that, in addition to immune-mediated mechanisms described in literature for ATT-induced AKI, other pathophysiological mechanisms might also be linked to this pathology and need further research for better understanding and optimization of treatment strategies.


Metrics Loading ...


1. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol. 2008;191(3):834–44.

World Health Organization. Tuberculosis (TB). Available from: Last updated Nov 7, 2023; cited Feb 07, 2023.

Sakashita K, Murata K, Takahashi Y, Yamamoto M, Oohashi K, Sato Y, et al. A case series of acute kidney injury during anti-tuberculosis treatment. Intern Med. 2019;58(4):521–7.

Chogtu B, Surendra VU, Magazine R, Acharya PR, Yerrapragada DB. Rifampicin-induced concomitant renal injury and hepatitis. J Clin Dian Res. 2016;10(9):0D18–9.

Covic A, Goldsmith DJA, Segall L, Stoicescu C, Lungu S, Volovat C, et al. Rifampicin-induced acute renal failure: A series of 60 patients. Nephrol Dial Transplant. 1998;13(4):924–9.

Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One. 2011;6(7):e21836.

Tsang JY, Murray J, Kingdon E, Tomson C, Hallas K, Campbell S, et al. Guidance for post-discharge care following acute kidney injury: an appropriateness ratings evaluation. BJGP Open. 2020;4(3):bjgpopen20X101054.

Beebe A, Seaworth B, Patil N. Rifampicin-induced nephrotoxicity in a tuberculosis patient. J Clin Tuberc Other Mycobact Dis. 2015;1:13–5.

Schubert C, Bates WD, Moosa MR. Acute tubulointerstitial nephritis related to antituberculous drug therapy. Clin Nephrol. 2010;73(6):413–9.

Chiba S, Tsuchiya K, Sakashita H, Ito E, Inase N. Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: A case report and literature review. Intern Med. 2013;52(21):2457–60.

Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002;40(4):690–6.

De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998;31(1):108–15.

Smith EL, Bywater L, Pellicano R, Jenkin GA, Korman TM. Acute Tubular Necrosis and Thrombocytopenia Associated with Rifampin Use: Case Report and Review. Open Forum Infect Dis. 2022;9(7).

Ata F, Magboul HMB, Toba HAA, Alfar H, Al Bozom A, Murshed K, et al. Rifampin‐induced acute kidney injury and hemolysis: A case report and literature review of a rare condition. Clin Case Rep. 2022;10(12):e6780.

Penn Medicine. Acute Kidney Injury (AKI) - Symptoms and Causes. Available from: Last updated Nov 4, 2022; cited Sep 14, 2022.

Chang CH, Chen YF, Wu VC, Shu CC, Lee CH, Wang JY, et al. Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. BMC Infect Dis. 2014;14(1):23.

Sharma AP, Sural S, Gupta A, Garg AX, Gulati S, Sharma RK. Effect of antitubercular medications on blood pressure control in chronic kidney disease patients with tuberculosis: a prospective cohort study. J Nephrol. 2006;19(6):771–7.

Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18(1):103–21.

Fiaccadori E, Sabatino A, Morabito S, Bozzoli L, Donadio C, Maggiore U, et al. Hyper/hypoglycemia and acute kidney injury in critically ill patients. Clin Nutr. 2016(2):317-21.

Beck Jr. LH, Salant DJ. Harrison’s Principles of Internal Medicine. 20th ed. New York: McGraw-Hill Education; 2018.

Moussa C, Esbaa S, Rouis H, Sellami N, Hajji M, Houcine Y, et al. Rifampicin‐induced acute tubulointerstitial nephritis during pulmonary tuberculosis treatment: A case report. Respirol Case Rep. 2023;11(8):e01190.

Moledina DG, Parikh CR. Differentiating acute interstitial nephritis from acute tubular injury: a challenge for clinicians. Nephron. 2019;143(3):211-6.

Clarkson MR, Giblin L, O’Connell FP, O’Kelly P, Walshe JJ, Conlon P, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778–83.

Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8–14.

Chest X-ray Showing Cavitary Lesion (shown by a Circle) and Consolidation in the Left Lung (shown by an Arrow).



How to Cite

Shaukat, M. A., Ali, M. F., Irtaza, A., Khan, S. Y., Khan , S. M., & Babar, S. (2024). Continuous Rifampicin Therapy Induced Acute Kidney Injury in a Tuberculous Patient: A Case Report. International Journal of Medical Students, 12(2), 212–218.